Literatur
- 1
Agrawal N M, Roth S, Graham D Y, White R H, Germain B, Brown J A, Stromatt S C.
Misoprostol
compared with sucralfate in the prevention of nonsteroidal anti-inflammatory
drug-induced gastric ulcer. A randomized, controlled trial.
Ann
Intern Med.
1991;
115
195-200
- 2
Agrawal N, Safdi M, Wruble L, Karvois D, Greski-Rose P, Huang B.
Effectiveness
of Lansoprazole in the healing of NSAID-induced ulcer in patients
continuing to take NSAIDs.
Gastroenterology (abstract).
1998;
114
A52-A53
- 3
Bianchi Porro G, Parente F, Imbesi V, Montrone F, Caruso I.
Role
of Helicobacter pylori in ulcer healing and recurrence of gastric
and duodenal ulcers in longterm NSAID users.
Gut.
1996;
39
22-26
- 4
Bradley J D, Brandt K D, Katz B P, Kalasinski L A, Ryan S I.
Comparison
of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen,
and acetaminophen in the treatment of patients with osteoarthritis
of the knee.
New Engl J Med.
1991;
325
87-91
- 5
Chan F K, Sung J J, Chung S C. et al .
Randomised controlled trial of Helicobacter
pylori before non-steroidal anti-inflammatory drug therapy to prevent
peptic ulcers.
Lancet.
1997;
350
975-979
- 6
Cullen D J, Hawkey G M, Greenwood D C. et al .
Peptic ulcer bleeding in the elderly: Relative
roles of Helicobacter pylori and nonsteroidal anti-inflammatory
drugs.
Gut.
1979;
41
459-462
- 7
Donnelly M T, Stack W A, Courtauld E M, Garlick N, Del Soldato P, Hawkey C J.
Nitric oxide
donating flurbiprofen (HCT 1026) causes less endoscopic damage in
healthy volunteers than flurbiprofen.
Gastroenterology
(abstract).
1998;
114
A107
- 8
Ehsanullah R S, Page M C, Tildesley G, Wood J R.
Prevention of
gastroduodenal damage induced by nonsteroidal antiinflammatory drugs: Controlled
trial of ranitidine.
Br Med J.
1988;
297
1017-1021
- 9
Ekstrom P, Carling L, Wetterhus S. et al .
Prevention of peptic ulcer and dyspeptic
symptoms with omeprazole in patients receiving continous non-steroidal
anti-inflammatory drug therapy. A Nordic multicentre study.
Scand
J Gastroenterol.
1996;
31
753-758
- 10
Gabriel S E, Jaakkimainen L, Bombardier C.
Risk
for serious gastrointestinal complications related to use of nonsteroidal
anti-inflammatory drugs. A meta-analysis.
Ann Intern Med.
1991;
115
787-796
- 11
Goldstein J L, Agrawal N M, Silverstein F. et al .
Celecoxib is associated with a significantly
lower incidence of clinically significant upper gastrointestinal
events in osteoarthritis and rheumatoid arthritis patients as compared
to NSAIDS.
Gastroenterology (abstract).
1999;
116
A174
- 12
Graham D Y, White R H, Moreland W. et al .
Duodenal and gastric ulcer prevention with
misoprostol in arthritis patients taking NSAIDs. Misoprostol Study
Group.
Ann Intern Med.
1993;
119
257-262
- 13
Hawkey C J, Karrasch J A, Szczepanski L, Walker D K, Barkun A, Swannell A J, Yeomans N D.
Omeprazole
compared with misoprostol for ulcers associated with nonsteroidal
antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced
Ulcer Management (OMNIUM) Study Group.
New Engl J Med.
1998;
338
727-734
- 14
Hawkey C J, Tulassay Z, Szczepanski L. et al .
Randomised controlled trial of Helicobacter
pylori eradication in patients on non-steroidal anti-inflammatory
drugs: HELP NSAIDs Study.
Lancet.
1998;
352
1016-1021
- 15
Huskisson E C, Ghozian R, Kurthen R, Degner F L, Bluhmki E.
A
long-term study to evaluate the safety and efficacy of meloxicam
therapy in patients with rheumatoid arthritis.
Br J Rheumatol.
1996;
35
29-34
- 16
Koch M, Dezi A, Ferrario F, Capurso I.
Prevention
of nonsteroidal anti-inflammatory drug-induced gastrointestinal
mucosal injury. A meta-analysis of randomized controlled clinical
trials.
Arch Intern Med.
1996;
156
2321-2322
- 17
Laine L, Hawkey C, Harper, Mortensen E, Beaulieu A, Quan H, Bolognese J, Simon T.
Effect of the COX-2 specific
inhibitor (C-2SI) rofecoxib on ulcer formation.
Gastroenterology
(abstract).
1999;
116
A229
- 18
Lancaster-Smith M J, Jaderberg M E, Jackson D A.
Ranitidine
in the treatment of nonsteroidal anti-inflammatory drug associated
with gastric and duodenal ulcers.
Gut.
1991;
32
69-75
- 19
Lanza F L, Rack M F, Callison D A. et al .
A pilot endoscopic study of the gastroduodenal
effects of SC-58635, a novel COX-2-selective inhibitor.
Gastroenterology
(abstract).
1997;
112
A194
- 20
Raskin J B, White R H, Jaszewski R, Korsten M A, Schubert T T, Fort J G.
Misoprostol and
ranitidine in the prevention of NSAID-induced ulcers.
Am
J Gastroenterol.
1996;
91
223-227
- 21
Robinson M G, Griffin J W, Bowers J, Kogan F J, Kogut D G, Lanza F L, Warner C W.
Effect
of ranitidine on gastroduodenal damage induced by nonsteroidal antiinflammatory
drugs.
Dig Dis Sci.
1989;
34
424-428
- 22
Roth S, Agarwal N, Mahowald M. et al .
Misoprostol
heals gastroduodenal injury in patients with rheumatoid arthritis
receiving aspirin.
Arch Intern Med.
1989;
149
775-779
- 23
Scheiman J M, Behier E M, Loeffler K M, Elta G H.
Omeprazole ameliorates aspirin-induced
gastroduodenal injury.
Dig Dis Sci.
1994;
39
97-103
- 24
Shorr R J, Ray W A, Daugherty J R, Griffin M R.
Concurrent
use of nonsteroidal anti-inflammatory drugs and oral anticoagulants
places elderly persons at risk for hemorrhagic peptic ulcer disease.
Arch
Intern Med.
1993;
153
1665-1670
- 25
Silverstein F E, Graham D Y, Senior J R, Davies H W, Struthers B J, Bittman R M, Geis G S.
Misoprostol
reduces serious gastrointestinal complications in patients with
rheumatoid arthritis receiving nonsteroidal anti-inflammtory drugs.
Ann
Intern Med.
1995;
123
241-249
- 26
Singh G, Ramey D R, Morfeld D, Shi H, Hatoum H T, Fries J F.
Gastrointestinal
tract complications of nonsteroidal anti-inflammatory drug treatment
in rheumatoid arthritis. A prospective observational cohort study.
Arch
Intern Med.
1996;
156
1530-1536
- 27
Taha A S, Hudson N, Hawkey C J. et al .
Famotidine for the prevention of gastric
and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.
New
Engl J Med.
1996;
334
1435-1439
- 28
Taha A S, Dahill S, Nakshabendi I. et al .
Duodenal histology, ulceration, and Helicobacter
pylori in the presence or absence of nonsteroidal anti-inflammatory
drugs.
Gut.
1993;
34
1162-1166
- 29
Ten-Wolde S, Dijkmans B A, Janssen M, Hermans J, Lamers C B.
High-dose
ranitidine for the prevention of recurrent peptic ulcer disease
in rheumatoid arthritis patients taking NSAIDs.
Aliment
Pharmacol Ther.
1996;
10
347-351
- 30
Walan A, Bader J P, Classen M. et al .
Effect
of omeprazole and ranitidine on ulcer healing and relapse rates
in patients with benign gastric ulcer.
New Engl J Med.
1989;
320
59-75
- 31
Walt R P.
Misoprostol
for the treatment of peptic ulcer and antiinflammatory-drug-induced
gastroduodenal ulceration.
New Engl J Med.
1992;
327
1575-1580
- 32
Yeomans N D, Tulassay Z, Juhasz L. et al .
A comparison of omeprazole with ranitidine
for ulcers associated with nonsteroidal anti-inflammatory drugs.
New
Engl J Med.
1998;
338
719-726
Korrespondenz
Dr. Miriam Thumshirn
Prof. Dr. Michael Fried
Abteilung für Gastroenterologie Departement
Innere Medizin Universitätsspital Zürich
Rämistrasse 100
CH-8091 Zürich
Fax: 0041/1/2554503
